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Background: Diabetes (DM) deteriorates the prognosis in patients with coronary heart disease. However, the
prognostic value of different glucose abnormalities (GA) other than DM in subjects with acute myocardial infarction
(AMI) treated invasively remains unclear.
Aims: To assess the incidence and impact of GA on clinical outcomes in AMI patients treated with percutaneous
coronary intervention (PCI).
Methods: A single-center, prospective registry encompassed 2733 consecutive AMI subjects treated with PCI. In all
in-hospital survivors (n = 2527, 92.5%) without the history of DM diagnosed before or during index hospitalization
standard oral glucose tolerance test (OGTT) was performed during stable condition before hospital discharge and
interpreted according to WHO criteria. The mean follow-up period was 37.5 months.
Results: The incidence of GA was as follows: impaired fasting glycaemia - IFG (n = 376, 15%); impaired glucose
tolerance - IGT (n = 560, 22%); DM (n = 425, 17%); new onset DM (n = 384, 15%); and normal glucose
tolerance – NGT (n = 782, 31%). During the long-term follow-up, death rate events for previously known DM, new
onset DM and IGT were significantly more frequent than those for IFG and NGT (12.3; 9.6 and 9.4 vs. 5.6 and 6.4%,
respectively, P < 0.05). The strongest and common independent predictors of death in GA patients were glomerular
filtration rate < 60 ml/min/1,73 m^2 (HR 2.0 and 2.8) and left ventricle ejection fraction < 35% (HR 2.5 and 1.8, all
P < 0.05) respectively.
Conclusions: Glucose abnormalities are very common in AMI patients. DM, new onset DM and IGT increase remote
mortality. Impaired glucose tolerance bears similar long-term prognosis as diabetes.
Keywords: Acute myocardial infarction, Glucose abnormalities, Diabetes mellitus, Percutaneous coronary
interventionIntroduction
The prevalence of type 2 diabetes mellitus (DM) has
rapidly increased worldwide over the last decades and
DM is increasingly perceived as an ongoing epidemic.
There is a conclusive evidence implicating DM in com-
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reproduction in any medium, provided the orand [4]. The risk of acute myocardial infarction (AMI)
and death in diabetic subjects without CHD is similar to
the risk of non-diabetic pts with previous AMI. There-
fore, DM has gained the status of CHD risk equivalent
[5]. Despite recent treatment improvements of AMI,
patients with DM have worse prognosis after myocardial
infarction in comparison to subjects without DM. There
is also evidence that CHD patients have glucose abnor-
malities (GA) other than DM. Mozaffarian et al. as well
as Bartnik et al. compared population-based cohorts of
patients with AMI and found that AMI groups showedl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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fasting glucose and diabetes. Therefore, they proposed
that myocardial infarction may be a prediabetes equiva-
lent [6] and [7]. However, the early and long-term out-
come in AMI patients with glucose abnormalities other
than DM remains unclear. The aim of our study was to
assess the incidence and prognostic role of different glu-
cose abnormalities in AMI patients treated with percu-
taneous coronary intervention (PCI) as well as to
identify independent predictors of death in GA.
Materials and methods
Data acquisition
A computerized database was used for prospective
collection of data from 2733 consecutive patients ad-
mitted with AMI to our department. Recorded data
included demographic and laboratory parameters,
concomitant diseases, characteristics of AMI, types of
glucose abnormalities, angiographic findings, out-
comes of revascularization procedure, in-hospital
complications and mortality. Data concerning long-
term outcome was collected from a database of the
National Fund of Health. The mean follow-up period
was 37.5 months and the data was collected from
99% of patients enrolled in the study.
Protocol of the registry
The study population consisted of 2733 consecutive
patients admitted to our Department with AMI and
treated in the acute phase with PCI between January
2003 and December 2007. In all in-hospital survivors
(n = 2527, 92.5%) without the history of diabetes mellitus
diagnosed before or during index hospitalization stand-
ard oral glucose tolerance test (OGTT) was performed
after stabilization of patients’ condition, routinely the
day before or on discharge day, however no sooner than
on day 5. Results of OGTT were interpreted in line with
WHO recommendations for GA diagnosis [8]. This
measure made it possible to diagnose the following glu-
cose abnormalities: IFG - impaired fasting glycaemia;
IGT - impaired glucose tolerance; DM - diabetes mellitus
diagnosed previously; new onset DM - diabetes mellitus
diagnosed during index hospitalization; and NGT -
patients with normal glucose tolerance. Patients with
IFG and IGT comprised a prediabetic group, while sub-
jects with both, previously diagnosed DM as well as with
the new onset DM represented the diabetic group. The
rest of the patients, without any glucose disturbances,
constituted the NGT group [Figure 1].
Measurements and definitions
Diagnosis of glucose abnormalities was based on WHO
criteria for venous plasma [8]. Patients were classified as
having DM if they reported current or previous use ofantidiabetic medications (insulin or oral hypoglycaemic
agents). A new onset DM was diagnosed if fasting gly-
caemia during hospitalization, but no sooner than on day
5 was ≥7.0 mmol/l on at least two occasions (17.7% of
cases) as well as on the basis of OGTT if fasting glycaemia
was ≥7.0 mmol/l or a two hour post-load glucose level
≥11.1 mmol/l. OGTT made it possible to diagnose the
new onset DM in 82.3% of cases. IFG was diagnosed if
fasting glucose was ≥6.1 but <7.0 mmol/l, and IGT if fast-
ing glucose was <7.0 mmol/l and postprandial glucose
level ≥7.8 but <11.1 mmol/l. Normal glucose tolerance
group consisted of patients with fasting glucose
<6.1 mmol/l, and 2 h post-load glucose level <7.8 mmol/l.
Clinical AMI criteria evaluated on admission were:
chest pain persisting > 20 min, ST segment elevation of
at least 0.1 mV in two or more continuous ECG leads or
non-diagnostic ECG with enzymatic confirmation of
AMI. The biochemical criterion of myocardial infarction
was elevated troponin I above the upper limit of normal.
The other biochemical markers of myocardial injury:
creatinine kinase (CK) and its isoenzyme MB (CK-MB)
were assessed in all subjects. Patients were mainly ad-
mitted from referral hospitals and previous administra-
tion of fibrinolytic treatment was allowed. No upper age
limit was used.
Duration of chest pain was estimated by the time
interval between chest pain onset and the time of arrival
to the emergency room. Multivessel disease was defined
as the presence of >2 major epicardial coronary arteries
or their major branches with stenosis of at least 70%,
assessed during initial coronary angiography. Complete
revascularization was defined when no total occlusion
and no residual stenosis >70% (for left main >50%) was
found in any major coronary artery or their major
branches at discharge.
The estimated glomerular filtration rate was calculated
using serum creatinine value on admission before
catheterization, according to the abbreviated Modifica-
tion of Diet in Renal Disease Study Group Equation pro-
posed by National Kidney Foundation. Contrast-induced
nephropathy (CIN) was defined as a rise in serum cre-
atinine of 44.2 μmol/L (0.5 mg/dL), or a 25% increase
from the baseline value within 48 h after PCI [9].
Treatment protocol
In all consecutive patients, coronary angiography and
PCI of infarct-related artery (IRA) were performed with
the use of standard techniques immediately after hospital
admission. All patients before coronary angiography
received a single dose of oral aspirin (300–500 mg) and
5000–10000 U of intravenous heparin (additional boluses
were given as appropriate to achieve activated clotting
time >250 ms). The goal of PCI was to restore
Thrombolysis in Myocardial Infarction (TIMI) 3 grade
Figure 1 Study population selection, AMI – acute myocardial infarction, OGTT – oral glucose tolerance test, DM new onset – newly
diagnosed diabetes mellitus, DM – diabetes mellitus diagnosed previously, IGT – impaired glucose tolerance, IFG – impaired fasting
glucose, NGT – normal glucose tolerance.
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denotes a successful procedure. After the intervention,
all patients received 150 mg of aspirin daily indefin-
itely, 300 mg clopidogrel just before PCI, followed by
250 mg ticlopidine twice daily or 75 mg clopidogrel
daily orally, as well as beta-blockers, ACE inhibitors/
angiotensin receptor blockers (ARB) and statins, if
these agents had not been contraindicated.
Hypoglycaemic treatment in the acute phase of AMI
was in line with the DIGAMI protocol [10]. In patients
with DM and blood glucose >11 mmol/l as well as in
those without the previous diagnosis of DM, but with
glucose levels over 11 mmol/l the insulin infusion was
administered for at least 24 h followed by daily subcuta-
neous insulin injections for the remainder of the hospital
stay and a minimum of 3 months thereafter. Every pa-
tient with the diagnosis of any type of GA was consulted
by a diabetology specialist before hospital discharge and
several issues with regard to lifestyle modification (body
weight normalization, physical activity, smoking cessa-
tion), diet and medication were addressed.Outcomes
The primary outcome was death from any cause. Second-
ary outcomes included one of the following events: either
recurrent myocardial infarction, repeated PCI, coronary
artery by-pass grafting or stroke. Major adverse cardio-
vascular event (MACE) was defined as the occurrence of
death or any of the above during observation period.Statistical analysis
Continuous parameters were expressed as means with
standard deviations unless otherwise specified, categorical
variables were presented as numbers and percentages.
Comparative analysis between groups was performed
using Student’s t-test for continuous variables and
Chi-square or Fisher’s exact test, as appropriate, fordichotomous parameters. Log-rank tests were used to
compare Kaplan-Meier curves plotted for cumulative sur-
vival and freedom from MACE. Independent predictors
of death were identified with multivariate Cox-regression
model and expressed as hazard ratio with 95% confidence
interval. Regression models were developed after the inclu-
sion of all parameters with significant univariate association
with appropriate end-point. All tests were double-sided.
P value <0.05 was considered statistically significant. All
analyses were performed using the software package
Statistica (version 6.1, StatSoft Inc., Tulsa, OK, USA).
The following variables were incorporated into the
multivariate analysis model in order to identify independ-
ent predictors of death in different glucose abnormalities:
age > 70 years, gender, prior stroke, prior AMI, previous
CABG, previous PCI, multivessel disease, Killip class and
cardiogenic shock on admission, hypertension, hyperlip-
idaemia, smoking, symptoms duration, IIb/IIIa inhibitors,
unsuccessful PCI of IRA (TIMI< 3 after PCI), previous
thrombolytic treatment, incomplete revascularization
(ICR), glomerular filtration rate (GFR), contrast induced
nephropathy (CIN), left ventricle ejection fraction (LVEF),
type of AMI (NSTEMI vs STEMI), type of infarct-related
artery (IRA), haematocrit, hemoglobin level.Ethics
All clinical data was obtained as the result of diagnostic
and therapeutic procedures, which were in line with treat-
ment guidelines for myocardial infarction. All patients
provided an informed, written consent for hospitalization,
invasive treatment and the use of collected data for re-
search purposes.Results
Baseline characteristics
Patients with DM and IGT were older, with lower fre-
quency of male gender and smokers, more often
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contrast-induced nephropathy. What is more, they had
higher Killip class and higher values of admission gly-
caemia as well as lower ejection fraction and glomerular
filtration rate in comparison to IFG and NGT groups.
Diabetic patients presented also with longer symptoms
duration, higher frequency of prior AMI, multivessel
coronary artery disease, incomplete revascularization, as
well as lower efficacy of PCI defined as TIMI flow < 3 of
IRA in comparison to other study groups.
The usage of beta-blockers, statins, ACE inhibitors/
ARB, acetylsalicylic acid, and clopidogrel/ticlopidine dur-
ing in-hospital period and prescribed at discharge did
not differ significantly between study groups [Table 1].Table 1 Comparative analysis of demographic, clinical and la
Variable DM (n = 425) New onse
Age (yrs) 65.5 ± 9.5* 65.3
Male – no. (%) 241 (56.7)* 237
Smoking – no. (%) 166 (39.1)* 182
Hypertension – no. (%) 320 (75.3)* 218
Hyperlipidaemia – no. (%) 232 (54.5)* 200
Peripheral vascular disease – no. (%) 42 (9.9)* 41
Creatinine on admission (μmol\L) 104.3 ± 86.6* 92.1
GFR (mL/min/1.73 m2) 73.3 ± 26.7* 77.6
Contrast-induced nephropathy – no. (%) 110 (25.8)* 127
Previous myocardial infarction – no. (%) 113 (26.5)* 75
Previous CABG – no. (%) 16 (3.8)* 1
Previous PCI – no. (%) 63 (14.8)* 3
Glucose on admission (mmol/L) 12.2 ± 5.4* 9.
Pain duration (hours) 7.9 ± 9.9* 7.9
Killip-class on admission 1.3 ± 0.7* 1.
Anterior infarction – no. (%) 144 (33.8)* 150
Ejection fraction (%) 42.0 ± 8.4* 42.
Fibrinolysis – no. (%) 10 (2.3)* 1
GP IIb/IIIa – inhibitor – no. (%) 68 (16.0)* 66
Beta-adrenergic blocker – no. (%) 372 (87.6)* 338
ACE-inhibitor/ARB – no. (%) 369 (86.9)* 328
Aspirin – no. (%) 414 (97.4)* 376
Statin – no. (%) 357 (83.9)* 323
Clopidogrel/Ticlopidine – no. (%) 369 (86.9)* 335
Multivessel coronary artery disease –no (%) 322 (75.8)* 252
Incomplete revascularization – no. (%) 240 (56.5)* 177
TIMI flow <3 after PCI of IRA – no. (%) 63 (14.9)* 70
Hospitalization time (days) 9.8 ± 7.9* 10.
Values presented as means ± SD or percentage of subjects. ARB = angiotensin recep
mellitus; GFR = glomerular filtration rate; GP IIb/IIIa = glycoprotein IIb/IIIa; IGT = impa
tolerance; IRA = infarct-related artery; PCI = percutaneous coronary intervention; TIM
* – p value <0.05 compared with normal glucose tolerance group (NGT).Long term outcome
Total mortality rate in the entire study population was
8.6%. There were no differences in 30-day mortality be-
tween all study groups. However, during 1-year follow-
up death rate events were significantly more frequent
both in DM and IGT in comparison to IFG and NGT
groups (9.0 and 6.7 vs. 2.9 and 3.7%, respectively,
P < 0.05). Similarly, during the long-term follow-up,
death rate events for previously known DM, new onset
DM and IGT were also significantly more frequent than
those for IFG and NGT groups (12.3; 9.6 and 9.4 vs. 5.6
and 6.4%, respectively, P < 0.05) [Table 2].
Incidence of MACE was significantly higher in DM
compared to other study groups in a 30-day follow-up.boratory data among study groups
t DM (n = 384) IGT (n = 560) IFG (n = 376) NGT (n = 782)
± 10.4* 62.3 ± 10.3* 58.2 ± 11.0* 57.0 ± 11.3
(61.6)* 395 (70.5)* 316 (82.4)* 618 (79.0)
(47.4)* 319 (56.9)* 245 (65.1)* 533 (68.2)
(56.9)* 302 (53.9)* 167 (44.3)* 325 (41.6)
(52.1)* 295 (52.6)* 208 (55.2)* 411 (52.5)
(10.8)* 48 (8.5)* 23 (6.1)* 61 (7.8)
± 39.2* 85.9 ± 34.0* 80.3 ± 18.7* 85.5 ± 42.5
± 25.6* 84.5 ± 25.2* 92.5 ± 24.5* 89.2 ± 25.6
(33.2)* 150 (26.8)* 79 (21.1)* 133 (17.0)
(19.6)* 95 (16.9)* 61 (16.3)* 132 (16.9)
0 (2.7)* 12 (2.2)* 10 (2.7)* 26 (3.3)
1 (8.2)* 54 (9.6)* 26 (7.0)* 66 (8.4)
6 ± 4.1* 7.8 ± 2.5* 7.2 ± 2.0* 7.2 ± 2.2
± 10.5* 5.8 ± 6.6* 5.7 ± 5.9* 5.9 ± 7.4
4 ± 0.8* 1.3 ± 0.6* 1.2 ± 0.5* 1.2 ± 0.5
(39.1)* 195 (34.8)* 143 (37.9)* 242 (31.0)
8 ± 8.3* 43.8 ± 7.8* 44.9 ± 7.7* 45.7 ± 7.0
0 (2.5)* 21 (3.8)* 8 (2.1)* 31 (4.0)
(17.3)* 80 (14.3)* 58 (15.5)* 84 (10.8)
(88.1)* 498 (88.9)* 327 (87.0)* 702 (89.8)
(85.4)* 483 (86.2)* 320 (85.2)* 672 (85.9)
(98.0)* 549 (98.0)* 369 (98.2)* 769 (98.3)
(84.0)* 471 (84.1)* 312 (83.1)* 658 (84.2)
(87.2)* 488 (87.1)* 325 (86.4)* 683 (87.4)
(65.7)* 346 (61.7)* 222 (59.1)* 456 (58.3)
(46.1)* 264 (47.1)* 172 (45.8)* 328 (41.9)
(18.1)* 72 (12.8)* 45 (12.1)* 77 (9.8)
3 ± 6.2* 8.9 ± 4.6* 7.7 ± 2.6* 7.6 ± 4.3
tor blockers; CABG= coronary artery by-pass grafting; DM= type 2 diabetes
ired glucose tolerance; IFG = impaired fasting glucose; NGT = normal glucose
I = Thrombolysis in Myocardial Infarction.
Table 2 Comparative analysis of the outcomes between study groups
DM (n = 425) New onset DM (n = 384)a IGT (n = 560)b IFG (n = 376)c NGT (n = 782)d
30-day outcome:
Myocardial infarction – no. (%) 4 (1.0) 5 (1.3) 10 (1.8) 6 (1.7) 13 (1.7)
PCI – no. (%) 16 (3.7) b 6 (1.6) 7 (1.3) 9 (2.4) 18 (2.3)
CABG – no. (%) 0 (0) 4 (1.0) d 4 (0.7) d 1 (0.3) 0 (0.0)
Stroke – no. (%) 1 (0.2) 1 (0.3) 1 (0.2) 2 (0.5) 2 (0.3)
Mortality – no. (%) 9 (2.1) 3 (0.8) 6 (1.0) 2 (0.5) 9 (1.1)
MACE – no. (%) 28 (6.6) c d 15 (4.0) 23 (4.1) 12 (3.2) 26 (3.3)
1-year outcome:
Myocardial infarction – no. (%) 63 (14.8) 42 (11.0) 86 (15.3) 59 (15.8) 106 (13.6)
PCI – no. (%) 90 (21.2) b 72 (18.8) 86 (15.3) 70 (18.6) 129 (16.5)
CABG – no. (%) 41 (9.6) 32 (8.3) 54 (9.7) 41 (10.9) 64 (8.2)
Stroke – no. (%) 7 (1.6) 9 (2.3) d 8 (1.4) 5 (1.3) 5 (0.6)
Mortality – no. (%) 38 (9.0) a c d 20 (5.2) 38 (6.7) c d 11 (2.9) b 29 (3.7)
MACE – no. (%) 174 (41.0) a c d 111 (29.0) b 208 (37.1) a c d 113 (30.0) b 229 (29.3)
Remote follow up:
Myocardial infarction – no. (%) 73 (17.2) 51 (13.3) 95 (17.0) 63 (16.8) 128 (16.4)
PCI – no. (%) 108 (25.4) b 88 (22.9) 103 (18.4) 79 (21.0) 166 (21.2)
CABG – no. (%) 49 (11.5) 32 (8.3) 55 (9.9) 46 (12.2) 72 (9.2)
Stroke – no. (%) 13 (3.1) 12 (3.1) 11 (2.0) 8 (2.1) 11 (1.4)
Mortality – no. (%) 52 (12.3) c d 37 (9.6) c d 53 (9.4) c d 21 (5.6) a b 50 (6.4)
MACE – no. (%) 187 (43.9) 153 (39.8) 227 (40.6) 152 (40.4) 310 (39.7)
Values presented as percentage of subjects. CABG= coronary artery by-pass grafting; DM= type 2 diabetes mellitus; IGT = impaired glucose tolerance;
IFG = impaired fasting glucose; NGT = normal glucose tolerance; MACE =major adverse cardiovascular event; PCI = percutaneous coronary intervention.
a – p value <0.05 compared with new onset DM group.
b – p value <0.05 compared with IGT group.
c – p value <0.05 compared with IFG group.
d – p value <0.05 compared with NGT group.
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events were more frequent in DM and IGT groups, dur-
ing the remote observation there were no significant dif-
ferences in MACE among all study groups [Table 2].
Cumulative survival rates in study groups with different
GA have been presented in Figure 2.
Independent predictors for death
The multivariate Cox-regression analysis revealed the in-
dependent predictors of death in GA patients [Table 3].
The strongest and common independent risk factors for
death in both prediabetic and diabetic group were glom-
erular filtration rate < 60 ml/min/1,73 m^2 (HR 2.0 and
2.8) and left ventricle ejection fraction < 35% (HR 2.5
and 1.8, all P < 0.05) respectively.
Discussion
Results of several cohort studies revealed that glucose
abnormalities other than DM are very frequent in
patients with CHD [11], [12] and [13]. The Euro Heart
Survey on Diabetes and the Heart showed that the ratesof normal glucose tolerance were less common than ab-
normal ones in patients with diagnosed CHD and that
over 50% of CHD subjects had IGT or newly detected
DM [12] and [14]. Our results confirmed the high preva-
lence of abnormal glucose metabolism in AMI patients,
with only 31% of subjects with normal glucose tolerance
and a high proportion of DM, IGT and IFG (32, 22 and
15% respectively).
Published data indicates also that hyperglycaemia is
associated with adverse outcomes regardless of dia-
betes status [15], [16] and [17]. Stress hyperglycaemia in
a setting of AMI increases the risk of malignant ventricu-
lar tachyarrhythmias as well as in-hospital mortality [16].
In the observational registry of consecutive nondiabetic
patients with STEMI Timmer et al. reported that acute
admission hyperglycaemia was associated with increased
1-year and remote mortality [17]. However, by means of
elevated admission glucose as well as HbA1c the
authors were able to identify the first parameter as the
predictor of early adverse outcomes, while the latter one
was independently associated with 1-year and long-term
Figure 2 Kaplan-Meier survival curves in particular study groups, NGT – normal glucose tolerance, New DM – newly diagnosed
diabetes mellitus, DM – diabetes mellitus diagnosed previously, IGT – impaired glucose tolerance, IFG – impaired fasting glucose, IFG
and control group vs IGT, new onset DM and DM; p< 0.05. IFG vs control group; p =NS. IGT vs new onset DM vs DM; p =NS. Time in
months.
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centration in diabetic patients in a setting of acute coron-
ary syndrome is not related to short-term cardiovascular
outcome [18].
It is known that patients with both CHD and DM have
worse outcomes than subjects with only one of these
two conditions [5], [19] and [20]. However, to the best of
our knowledge, there is very limited data on the impact
of different glucose perturbations on early and late clin-
ical outcomes in AMI patients treated with PCI in the
acute phase of myocardial infarction. Lenzen et al. in a
population of coronary artery disease showed that
patients with previously recognized DM are at highest
risk for adverse events, while those with newly detected
DM are at intermediate risk. Nevertheless, IFG and IGT
were not identified as independent predictors of worse
outcome. What is more, acute coronary syndromes
accounted for only 36% of patients in this study [14]. In
GAMI study, the analysis of AMI population with coex-
isting abnormal glucose tolerance revealed that both
IGT and newly diagnosed DM are strong andTable 3 Independent risk factors for death
Independent predictors
of death
Prediabetic group Diabetic group
HR 95% CI p HR 95% CI p
GFR< 60 ml/min/1,73 m^2 2.03 1.43-2.63 0.02 2.84 2.37-3.31 <0.01
LVEF < 35% 2.52 1.96-3.08 <0.01 1.82 1.29-2.35 0.029
Age> 70 yrs 2.20 1.7-2.7 <0.01 1.39 0.92-1.86 0.17
GFR - glomerular filtration rate.
LEVF – left ventricle ejection fraction.independent predictors of adverse cardiovascular events
after myocardial infarction [13]. However, of note is that
the GAMI population was relatively small and consisted
of only 168 subjects. The group with abnormal glucose
tolerance included 113 patients not only with IGT, but
also with a newly detected DM. What is more, reperfu-
sion therapy had been used only in 38% of patients with
glucose abnormalities and in 51% with normal glucose
regulation.
Our registry encompassed 2527 consecutive in-
hospital AMI survivors, who were optimally treated,
both pharmacologically and invasively (reperfusion by
means of PCI only) in the acute phase of AMI. Total
mortality rate of 8.6% in our study was relatively low.
However, this may be a result of the study protocol,
which was based on the analysis of in-hospital survi-
vors (n = 2527, 92.5%) in order to assess properly the
outcomes of AMI patients with different glucose ab-
normalities, in particular with GA other than previ-
ously diagnosed DM. Indeed, it would be impossible
to diagnose accurately and reliably GA other than
previously diagnosed DM in patients who died during
hospitalization. Among 206 subjects with AMI
(n = 7.5%) who died during index hospitalization 107
(52%) subjects had previously diagnosed DM. What is
more, all consecutive patients with AMI were treated
very homogenously and optimally both pharmaco-
logically and invasively with modern therapy (PCI), in
line with ESC recommendations and this may have
contributed to the relatively low long-term mortality.
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tively the outcomes of AMI patients treated invasively in
the acute phase of myocardial infarction. What is more,
the long-term prognosis of patients with IGT is similar
to the outcomes of AMI subjects with DM and signifi-
cantly worse than in normoglycaemic patients. Both,
IGT and DM increase significantly one year and remote
mortality in AMI population.
Moreover, further multivariate analysis model identi-
fied independent predictors of death in subjects with
glucose abnormalities. Impaired renal function along
with depressed left ventricle ejection fraction appeared
to be the strongest and common risk factors for death in
both prediabetic and diabetic groups. On a similar study
population Kowalczyk et al. found that the prognosis of
diabetics with AMI is related to renal function and dia-
betes coexisting with chronic kidney disease (CKD) is
one of the strongest independent risk factors for cardio-
vascular complications and total mortality [21]. Simi-
larly, Kim et al. in a nationwide prospective Korea Acute
Myocardial Infarction Registry (KAMIR) showed that
compromised renal function, in particular in combin-
ation with diabetes, is associated with the occurrence of
composite MACE and indicates poor prognosis in sub-
jects with AMI [22]. The impact of abnormal glucose
metabolism on left ventricular function and prognosis in
AMI patients was assessed by Høfsten et al. who demon-
strated a linear association between GA and left ventricu-
lar dysfunction [23]. What is more, Juana A Flores-Le
Roux et al. reported that in subjects with acute decom-
pensation of heart failure, a new onset diabetes is not
only common, but also increases remote mortality in the
same manner as previously diagnosed diabetes [24].
Our results thus confirmed an observation, that large
proportion of AMI patients has IGT as well as that this
type of abnormal glucose metabolism indicates the
group of patients at a high risk of adverse cardiac events.
Therefore, interventions which would improve the prog-
nosis in this group of AMI patients should be consid-
ered. Published data indicates that smoking cessation,
prevention of weight gain, and consumption of low-fat
dairy products could substantially lower this risk [6] and
[25]. However, although AMI individuals are usually
scheduled to follow these recommendations, our results
suggest that this type of strategy is insufficient.
Although it has been suggested, that IGT may be a
more “benign” state than DM the results of our registry
indicate, that both IGT and DM bear poor prognosis in
AMI patients [6]. The intriguing convergence of survival
Kaplan-Meier curves in diabetic and IGT-patients who
survived AMI may be explained by different treatment
strategies in both groups. Diabetic patients, in contrast
to IGT subjects, receive glucose-lowering medications
during acute AMI phase and throughout the follow-upperiod. Consequently, the beneficial effect of such a
pharmacotherapy only in DM subjects could be respon-
sible for similar long-term prognosis in both groups.
Up to date, only a few studies examined the effects of
antidiabetic treatment in IGT subjects [25], [26] and
[27]. However, the STOPNIDDM trial revealed very op-
timistic results [25] and [26]. In this randomized,
placebo-controlled trial Acarbose – oral anti-diabetic
agent, significantly prevented or delayed the progression
of glucose intolerance to diabetes and, most importantly,
significantly reduced the risk of cardiovascular events.
These data provided a strong rationale for the use of
similar agents as a part of treatment strategy in AMI
patients with coexisting IGT to improve long-term
prognosis.
Some recently published trials also indicated that life-
style modification and various pharmacological agents
can delay or prevent the development of glucose distur-
bances to overt diabetes. However, the expected rates of
cardiovascular events in these studies were low and did
not provide statistical power to evaluate the influence of
such interventions on MACE [28], [29] and [30]. The re-
cently published, promising study in this area was The
Navigator trial. The study was designed to evaluate
whether reducing postprandial hyperglycaemia and
blockade of the renin-angiotensin-aldosterone system or
both interventions reduce the risk of diabetes and car-
diovascular events in patients with IGT [31]. However,
after a median follow up of 6.5 years, neither valsartan
nor nateglinide improved cardiovascular prognosis in
the study population. What is more, nateglinide did not
reduce the risk of new onset diabetes, while valsartan
reduced this risk only by 14% [32] and [33]. The above
mentioned conflicting data from different studies indi-
cates the need for further randomized clinical trials in
order to establish the position of glucose-lowering
agents in prevention of adverse cardiovascular events in
AMI patients.
Clinical implications
Our data confirmed the importance of OGTT performed
before hospital discharge in detection of glucose abnor-
malities in non-diabetic AMI patients. Similarly to dia-
betic patients, subjects with IGT who survived
myocardial infarction treated with PCI in the acute
phase have unfavorable long-term prognosis. Further
studies are necessary to evaluate the role of new, add-
itional methods of treatment, possibly including glucose
lowering agents to improve prognosis in this high-risk
group of patients.
Limitation of the study
This is a single center, observational registry. Differences
in baseline characteristics among study groups are a
Mazurek et al. Cardiovascular Diabetology 2012, 11:78 Page 8 of 9
http://www.cardiab.com/content/11/1/78result of the registry protocol, which allowed to enroll
consecutive in-hospital AMI survivors who were treated
with PCI in the acute phase of myocardial infarction.
Neither OGTT was repeated in the follow-up period nor
details regarding further hypoglycaemic treatment are
available.
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